The FDA approved olaparib (Lynparza, AstraZeneca) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm), metastatic castration-resistant prostate cancer (mCRPC), as determined by an FDA-approved companion diagnostic test.
Efficacy was evaluated in the PROpel trial that enrolled 796 patients with mCRPC. Patients were randomized in a 1:1 fashion to receive either olaparib with abiraterone or placebo with abiraterone and
JUNE 2, 2023